BrainsGateforIVA

Information about BrainsGateforIVA

Published on November 16, 2007

Author: Coralie

Source: authorstream.com

Content

Company Presentation:  Company Presentation BioMed, 30 May 2006 Challenges in treating the Central Nervous System:  Challenges in treating the Central Nervous System Stroke Third leading cause of death in the western world First cause of long term disability Annual worldwide direct cost of stroke-related care is over $100B Window for treatment is currently 3-6 hours Drug delivery for diseases of the brain Brain tumors Alzheimer Parkinson Lysosomal Storage Diseases (e.g. Gaucher type II, III) Brain infections … The Blood-Brain Barrier (BBB):  The Blood-Brain Barrier (BBB) The BBB is formed by the brain capillary endothelium It excludes from the CNS Almost all large-molecules (MW > 500 Da) ~98% of small molecule drugs By far the biggest obstacle to CNS drug development Reference: Pardridge W., NeuroRx. 2:3-14, 2005 BrainsGate’s approach:  BrainsGate’s approach The spheno-palatine ganglion (SPG): A small nerve mass residing behind the nose Heart shaped, about 6mm long In the last 10 years was found to controls vasodilatation of cerebral blood vessels In: rats, cats, dogs, monkeys and humans BrainsGate has developed a device to stimulate the SPG Access to the SPG :  Access to the SPG The greater palatine canal: a natural approach Leads from SPG to a point near the third molar The NeuroPathTM implant is designed for insertion into the canal Procedure comparable to going to the dentist SPG stimulation through skin using electric coupling The system in use:  The system in use The Neuropath system was used on 10 patients in clinical trials Application – Ischemic Stroke:  Application – Ischemic Stroke Vasodilatation:  Vasodilatation Increasing vessel diameter was observed during preclinical and clinical trials Vasodilation can play a major role in stroke treatment Stimulated Non Stimulated Dog brain Yarnitsky et al., Surg Neurol. 2005 Jul;64(1):5-11 Infarct size reduction :  Infarct size reduction In pre clinical studies SPG stimulation caused Infarct size reduction Improved neuro-score Control Stimulation Improved mobility:  Improved mobility Stroke SPG stimulation Memory improvement:  Control SPG stimulated 1h SPG stimulated 6h SPG stimulated 10h Trial 1 Trial 2 Trial 3 Water Maze Test –time to platform Best improvement at 6 hours of stimulation Memory improvement Stroke - Summary:  Stroke - Summary Preclinical evidence Vasodilatation Infarct size reduction Improved motor function Improved cognitive function Large window of opportunity Treatment initiation – up to 24h 3-6 hours of treatment a day for 7 days Clinical trials to begin in H2’06 Application – CNS Drug Delivery:  Application – CNS Drug Delivery Affecting BBB permeability in rats:  Affecting BBB permeability in rats Model: rat Marker: Evans Blue solution Treatment: Unilateral electrical stimulation applied to post SPG nerve fiber Endpoint: visual inspection of brain Affecting the BBB in dogs:  Affecting the BBB in dogs Model: dog Marker: FITC-dextran Treatment: Unilateral SPG exposure and direct stimulation Endpoint: Analysis of marker levels ipsi- and contra-laterally Clinical data:  Clinical data The NeuroPath system was implanted in a 10 pt Brain Tumor Study Conclusions: Implantation procedure – Safe and Feasible Stimulation - tolerable Efficacy Vasodilatation evidence Traces of chemotherapy in CSF Surrogate marker (S100) in plasma About Us:  About Us BrainsGate – the company:  BrainsGate – the company An Israeli medical device company, founded 2000 To date, has raised $23M from leading investors Boston Scientific, Pitango Venture Capital, Alice Ventures, Infinity Venture Capital, Elron Electronic Industries An integrated team of professionals Neurological & Neuro Surgical physicians CNS scientists Pre-clinical and clinical experts Electrical and mechanical R&D Extensive pre-clinical and clinical data gathered Comprehensive IP portfolio Summary:  Summary SPG stimulation is a promising new modality for CNS therapy BrainsGate’s mission is to develop and commercialize this modality as a platform Based on current promising data our strategy is: Initiate clinical trials for Ischemic Stroke in H2’06 Seek collaborations with pharma companies targeting drug delivery to the CNS Thank you for your time!:  Thank you for your time!

Related presentations


Other presentations created by Coralie

Grapes of Wrath PowerPoint
05. 11. 2007
0 views

Grapes of Wrath PowerPoint

FI110
09. 10. 2007
0 views

FI110

08 Multiplexing
29. 11. 2007
0 views

08 Multiplexing

Equilibrium
12. 12. 2007
0 views

Equilibrium

FARMASYS
07. 11. 2007
0 views

FARMASYS

New Employee Orientation 2005
13. 12. 2007
0 views

New Employee Orientation 2005

ASPNET AJAX
27. 11. 2007
0 views

ASPNET AJAX

SPC Presentation Leitrim Part 1
01. 01. 2008
0 views

SPC Presentation Leitrim Part 1

RICH detectors
04. 01. 2008
0 views

RICH detectors

UoW conf 06 E Markou
18. 12. 2007
0 views

UoW conf 06 E Markou

Racial Stigma
07. 01. 2008
0 views

Racial Stigma

46th ICAAC2006
29. 10. 2007
0 views

46th ICAAC2006

jef431e lec 2
13. 11. 2007
0 views

jef431e lec 2

Alternative Schools
05. 11. 2007
0 views

Alternative Schools

GHFBSEC Istanbul 22006SOYAK
23. 11. 2007
0 views

GHFBSEC Istanbul 22006SOYAK

SenateHearing2000
15. 11. 2007
0 views

SenateHearing2000

ECOL 182L LAB7
30. 12. 2007
0 views

ECOL 182L LAB7

Japaneselanguage
06. 12. 2007
0 views

Japaneselanguage

lri dbs
07. 01. 2008
0 views

lri dbs

2007 4282S2 9
21. 11. 2007
0 views

2007 4282S2 9

The American Revolution
28. 02. 2008
0 views

The American Revolution

Ruth Oniango
04. 03. 2008
0 views

Ruth Oniango

dietaryguidelines
06. 03. 2008
0 views

dietaryguidelines

Canada schools 2008
11. 03. 2008
0 views

Canada schools 2008

Rod Johnson
12. 03. 2008
0 views

Rod Johnson

AmadeusWebinar
14. 03. 2008
0 views

AmadeusWebinar

augusti
18. 03. 2008
0 views

augusti

Vito Borelli
21. 03. 2008
0 views

Vito Borelli

articles 71120 anumita
27. 03. 2008
0 views

articles 71120 anumita

CRL Feb19 2004
30. 03. 2008
0 views

CRL Feb19 2004

302 06
13. 04. 2008
0 views

302 06

forteensandparents
25. 12. 2007
0 views

forteensandparents

pres9
04. 01. 2008
0 views

pres9

hf
03. 01. 2008
0 views

hf

Limours Cryptographie
05. 01. 2008
0 views

Limours Cryptographie

EIR Bridges By Harry Baker
29. 12. 2007
0 views

EIR Bridges By Harry Baker

Szwarc
07. 01. 2008
0 views

Szwarc

ponder RegTren Turkey
26. 11. 2007
0 views

ponder RegTren Turkey

1328 08 2003
16. 11. 2007
0 views

1328 08 2003

PPT06
20. 11. 2007
0 views

PPT06

Water Tank Presentation
08. 11. 2007
0 views

Water Tank Presentation

Framtid MS utvecklingsplattform
28. 11. 2007
0 views

Framtid MS utvecklingsplattform

Lazer
23. 12. 2007
0 views

Lazer